A realistic price and the offer of risk-sharing could help alternative pricing agreements be more attractive to AMGROS, Denmark’s procurement agency for hospital medicines, according to the body’s CEO, Flemming Sonne. AMGROS wants to capitalize on industry’s growing interest in these agreements and ensure they are better able to help deliver high cost innovation to patients.
Denmark Takes A Deep Dive Into Improving Alternative Drug Pricing Agreements
The Danish procurement body for hospital medicines, AMGROS, wants to better understand how to make alternative pricing agreements work and is inviting companies to take part in “deep dive dialogue” to ensure industry proposals hit the mark.
